Xenon Pharmaceuticals Inc Corporate Update Transcript
Good day and thank you for standing by. Welcome to the Xenon Pharmaceuticals corporate update conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sherry Aulin, Chief Financial Officer. Please go ahead.
Good morning, everyone. My name is Sherry Aulin, Xenon's Chief Financial Officer, and I will be moderating the call this morning. Thank you for joining us to discuss our top-line results from the Phase 2 proof-of-concept X-NOVA clinical trial of XEN1101 for the treatment of major depressive disorder, or MDD.
Joining me on today's call are Ian Mortimer, Xenon's President and Chief Executive Officer; and Dr. Chris Kenney, Xenon's Chief Medical Officer. Dr. Chris Von Seggern, Xenon's Chief Commercial Officer, will join us for the Q&A session following our prepared remarks.
For those of you on the webinar, there are slides accompanying today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |